About nanoviricides inc - NNVC
NanoViricides, Inc. is a clinical stage company, which engages in the development of nano-biopharmaceutical drugs against viruses. It focuses on anti-viral therapeutics through internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.
NNVC At a Glance
NanoViricides, Inc.
1 Controls Drive
Shelton, Connecticut 06484
| Phone | 1-203-937-6137 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -8,218,509.00 | |
| Sector | Health Technology | Employees | 7 | |
| Fiscal Year-end | 06 / 2027 | |||
| View SEC Filings |
NNVC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.657 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.221 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
NNVC Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,174,072.714 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
NNVC Liquidity
| Current Ratio | 2.656 |
| Quick Ratio | 2.656 |
| Cash Ratio | 2.347 |
NNVC Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -87.909 |
| Return on Equity | -101.46 |
| Return on Total Capital | -94.652 |
| Return on Invested Capital | -101.46 |
NNVC Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |